Needham on Hims and Hers (HIMS): 'we believe this incremental near-term investment and likely growing pains'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Hims and Hers (HIMS) PT Lowered to $48 at Jefferies, 'want to see proof points of consumer traction'
November 4, 2025 8:06 AM ESTJefferies analyst Glen Santangelo lowered the price target on Hims and Hers (NYSE: HIMS) to $48.00 (from $51.00) while maintaining a Hold rating.
The analyst comments "HIMS delivered a solid Q3, with revs, EBITDA, & EPS beating Street ests by 3%, 15%, & 30% respectively. EBITDA margins of 13.1% beat Street... More
Hims and Hers (HIMS) PT Raised to $32 at BofA Securities
November 4, 2025 5:10 AM ESTBofA Securities analyst Allen Lutz raised the price target on Hims and Hers (NYSE: HIMS) to $32.00 (from $28.00) while maintaining a Underperform rating.
The analyst comments "HIMS reported a mixed quarter with revenue/EBITDA exceeding Street/BofA estimates and total subscribers falling below expectations (see our first take report). The Sexual... More
BTIG Hims and Hers (HIMS): 'MAHA is being Implemented through HIMS with Proactive Health'
November 4, 2025 4:35 AM ESTBTIG analyst David Larsen reiterated a Buy rating and $85.00 price target on Hims and Hers (NYSE: HIMS).
The analyst comments "On Monday, 11/3/25 AMC, HIMS reported good 3Q:25 results. Revenue of $599M +49% y/y exceeded BTIG / consensus / guidance of $580.1M / $580M / $570M-$590M and adjusted EBITDA of $78.4M +53% y/y also came in well ahead of BTIG / consensus / guidance of $70.5M / $68M / $60M-$70M. HIMS... More
Canaccord Genuity Reiterates Buy Rating on Hims and Hers (HIMS)
November 4, 2025 3:20 AM ESTCanaccord Genuity analyst Maria Ripps reiterated a Buy rating and $68.00 price target on Hims and Hers (NYSE: HIMS).
The analyst commented: "Hims reported strong Q3 results, with both revenue and adj. EBITDA exceeding guidance. Excluding the impact of the ongoing transition within on-demand sexual health, subscribers grew 40% y/y, and Hims is also seeing sustained success cross-selling treatments, with multi-condition subscribers up 80% y/y and now representing 20% of total subscribers. Ongoing efforts to build out its vertically integrated operational... More
After-hours movers: Palantir, Hims & Hers Health, Sarepta Therapeutics, Sanmina
November 3, 2025 4:41 PM ESTAfter-hours movers:
Palantir (NASDAQ: PLTR) rose 2% after reporting solid quarterly results and better than expected guidance. Palantir sees Q4 2025 revenue of $1.327-1.331 billion, versus the consensus of $1.18 billion.
Hims & Hers Health (NYSE:... More
Hims and Hers tops revenue estimates as telehealth provider attracts more users
November 3, 2025 4:19 PM ESTBy Kamal Choudhury and Amina Niasse
(Reuters) -Hims and Hers Health beat Wall Street estimates for third-quarter revenue on Monday, as the telehealth company added subscribers and expanded its personalized healthcare offerings.
The company and rivals have launched programs that offer "personalized" versions of semaglutide, the active ingredient in Novo Nordisk's weight-loss drug Wegovy, at doses not accessible through the branded manufacturers, following the government's ban on the mass production of copies.
Hims & Hers said it was in active talks with Novo to offer Wegovy injections and, once approved, an oral version through its platform.
... MoreHims & Hers in talks with Novo Nordisk to offer Wegovy treatments
November 3, 2025 4:10 PM ESTHims & Hers Health Inc. (NYSE: HIMS) announced it is in discussions with Novo Nordisk A/S (NYSE: NVO) to potentially offer Wegovy injections and an oral version of Wegovy through its platform, pending FDA approval of the oral... More
Hims & Hers Health, Inc. (HIMS) Misses Q3 EPS by 4c, Offers Guidance
November 3, 2025 4:09 PM ESTHims & Hers Health, Inc. (NYSE: HIMS) reported Q3 EPS of $0.06, $0.04 worse than the analyst estimate of $0.10. Revenue for the quarter came in at $600 million versus the consensus estimate of $580.37 million.
GUIDANCE:
Hims & Hers Health, Inc. sees Q4 2025 revenue of $605-625... More
Hims & Hers Health, Inc. (HIMS) call put ratio 1.4 calls to 1 put into quarter results
November 3, 2025 10:17 AM ESTHims & Hers Health, Inc. (NYSE: HIMS) November 7 weekly call option implied volatility is at 171, November is at 111; compared to its 52-week range of 67 to 145. Call put ratio 1.4 calls to 1 put into the expected release of quarter results today after the bell.
... MoreHims & Hers Health, Inc. (HIMS) call put ratio 1.4 calls to 1 put into quarter results
October 31, 2025 10:29 AM EDTHims & Hers Health, Inc. (NYSE: HIMS) November 7 weekly call option implied volatility is at 34, November is at 112; compared to its 52-week range of 67 to 145. Call put ratio 1.4 calls to 1 put into the expected release of quarter results after the bell on November 3.
... MoreHims & Hers Health, Inc. (HIMS) call put ratio 1.1 calls to 1 put into quarter results
October 31, 2025 4:26 AM EDTHims & Hers Health, Inc. (NYSE: HIMS) November 7 weekly 44 straddle priced for a move of 17%. Call put ratio 1.1 calls to 1 put into the expected release of quarter results after the bell on November 3.
... More